June 3, 2016

Montreal-based producer of sustainable microbial crop accelerators, Inocucor Technologies Inc., announced that it has raised an additional $6 million in an extended Series A round of financing.

The round now includes Montreal-based venture capital fund, Cycle Capital Management, Desjardins Innovatech, Canada’s top cooperative financial group, Michigan-based family-run office, Red Metal Capital, and Philadelphia-based early stage agtech and food fund, Closed Loop Capital.

Inocucor uses technology similar to that used in winemaking, incorporating 15 different strains of yeast and bacteria to produce biological solutions that improve seed germination and improve crop yield through the building of healthier soil.

Inocucor’s growth strategy focuses on forging partnerships using its intellectual property as a key element of the development of new bio-protection and bio-stimulant products. In October 2014 Inocucor signed an agreement with McGill University to produce a new class of sustainable bio-stimulant production for large scale agriculture that will have the potential to increase crop yields by 10% to 15%.

“Our business model calls for a range of bio-based products that ultimately will help farmers feed a growing population with fewer or no chemical inputs,” said Donald R. Marvin, president and CEO of Inocucor, in a press statement.

The company has also announced that in June it plans to launch a follow-on equity financing round to fund the opening of a U.S. office. It also plans to expand its large-scale field trials and commercialization efforts in North and South American markets for its range of biological formulations and compounds.

Original Story:

CYCLE CAPITAL MANAGEMENT AND DESJARDINS INNOVATECH INVEST IN INOCUCOR TECHNOLOGIES

February 4, 2015

Montreal-based ag biotech firm, Inocucor Technologies Inc. has secured an interim round of capital from venture capital fund, Cycle Capital Management, which made its first investment in the company in 2013, and Desjardins Innovatech, a cooperative financial group with more than $200 billion in assets.

Inocucor uses technology similar to that used in winemaking, incorporating 15 different strains of yeast and bacteria to produce biological solutions that improve seed germination and improve crop yield through the building of healthier soil.

Inocucor’s growth strategy focuses on forging partnerships using its intellectual property as a key element of the development of new bio-protection and bio-stimulant products. In October 2014 Inocucor signed an agreement with McGill University to produce a new class of sustainable bio-stimulant production for large scale agriculture that will have the potential to increase crop yields by 10% to 15%, and this investment will support the firm’s commercialization of its ‘second generation cell-free bio-stimulant product’.  The funds will also be used to acquire additional technologies and products currently being investigated and screened by the company.

—

GAI News staff